Rating Change
Wedbush reiterated its Outperform rating on Avalo Therapeutics, Inc. (NASDAQ:AVTX) on October 23, 2026.
Wedbush reiterated its Outperform rating on Avalo Therapeutics, Inc. (NASDAQ:AVTX) on October 23, 2026.

At publication ·
Avalo Therapeutics, Inc. (NASDAQ:AVTX) · reiterate
At a glance
Wedbush reiterated its Outperform rating on Avalo Therapeutics, Inc. (NASDAQ:AVTX) on October 23, 2026.
Avalo Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $6.93 with a market capitalization of $220.3M.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Avalo Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 23, 2026 | Guggenheim | Neutral | N/A |
| Oct 23, 2026 | Wedbush | Outperform | N/A |
| Oct 23, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Oct 23, 2026 | BTIG | Buy | N/A |
| Aug 07, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View AVTX Stock Page
A rating of Outperform from Wedbush reflects the analyst's outlook on Avalo Therapeutics, Inc. (NASDAQ:AVTX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the AVTX forecast page.
Current market data
NASDAQ · AVTX
Keep reading